Gilead Adds 45-Day Lookback Clause to its 340B Contract Pharmacy Policy

Image of Harvoni pill bottle and pill
Gilead had added 45-day time limits for replenishment orders and claims submissions under its 340B contract pharmacy restrictions on Harvoni and its other branded hepatitis C medicines.

Drug manufacturer Gilead on Wednesday added 45-day time limits for replenishment orders and claims submissions to its conditions on 340B pricing when covered entities use contract pharmacies.

Ten manufacturers require covered entities to provide claims data to industry contractor 340B

Read More »

Exclusive: 340B Entities Report Unannounced and Unexplained Claims Reversals Involving CVS and Blue Cross Blue Shield

Blue Cross Blue Shield wordmarks
Providers say claims have been reversed without notice or explanation for 340B-purchased drugs that CVS Specialty dispensed to BCBS FEP participants.

UPDATE Wednesday, June 22, 2022, 2:50 p.m. EDT—CVS Health issued this statement: “We do not comment on specific PBM client contract terms. Our clients are sophisticated purchasers, and we work closely with them to customize a benefit design meeting their

Read More »

Feds Urge Appeals Court to Overrule Lower Court in AstraZeneca’s 340B Contract Pharmacy Lawsuit

AstraZeneca wordmark building-mounted sign
The federal government wants an appeals court to rule that drug manufacturer AstraZeneca may not unilaterally dictate how many contract pharmacies a 340B covered entity may use to dispense 340B drugs.

The federal government told a federal appeals court in Philadelphia yesterday it should use “the familiar tools of statutory interpretation” to hold that drug manufacturer AstraZeneca may not unilaterally dictate how many contract pharmacies a 340B covered entity may use

Read More »

West Virginia Hardens its 340B Anti-discrimination Law to Explicitly Bar 340B Claims Modifiers

Charleston Area Medical Center exterior sign and building
West Virginia has reinforced a 2019 law to bar PBMs or other payers from requiring hospitals such as CAMC and other health care providers to include claims modifiers when billing for 340B-purchased drugs.

West Virginia has reinforced its groundbreaking 2019 law forbidding what providers say is pharmacy benefit manager discrimination against 340B covered entities.

An amendment passed in March that took effect June 10 clarifies that PBMs or other third-party payers may not require a

Read More »

News Alert

NACHC Asks HHS to Swiftly Punish Drug Makers for 340B Pricing Denials Involving Contract Pharmacies

A letter from NACHC to HHS Secretary Xavier Becerra
NACHC urged HHS Secretary Xavier Becerra to hold drug manufacturers accountable for restricting shipments of 340B drugs to contract pharmacies.

The National Association of Community Health Centers (NACHC) strongly urged the U.S. Health and Human Services Secretary Xavier Becerra yesterday “to swiftly impose” fines on drug manufacturers that restrict shipments of 340B-purchased drugs to contract pharmacies and “hold manufacturers accountable

Read More »

News Alert

New Study Finds 340B Contract Pharmacy Growth in Affluent and White Neighborhoods, Hospitals Criticize Research

screenshot of a JAMA Health Forum research letter
340B contract pharmacy grew in affluent and White neighborhoods from 2011 to 2019 but declined in impoverished, Black, and Latino neighborhoods, a study published in JAMA Health Forum found. AHA strongly criticized the study.

340B contract pharmacy grew in affluent and White neighborhoods from 2011 to 2019 but declined in impoverished, Black, and Latino neighborhoods, raising questions about “the degree to which 340B program growth serves vulnerable communities,” according to research published this morning

Read More »

The Supreme Court Aftermath: What Comes Next in Fight Over Medicare Part B Drug Payments to 340B Hospitals?

The U.S. Supreme Court building and entrance plaza
Yesterday's U.S. Supreme Court's opinion about deep cuts in 340B hospitals’ Medicare Part B drug reimbursement ended Phase 1 of the debate. Phase 2 gets underway next month in lower federal courts in Washington, D.C., and in the pages of the Federal register.

Yesterday, the U.S. Supreme Court ruled that huge cuts in 340B hospitals’ Medicare Part B drug reimbursement in 2018 and 2019 were unlawful. It marked the end of Phase 1 of the debate over the cuts.

Phase 2 is gearing

Read More »

Bipartisan U.S. House Group Renewing Pressure on HHS to Punish Drug Makers Over 340B Pricing Denials

Headshots of U.S. House gang of six Representatives Spanberger, Axne, McKinley, Matsui, Katko, Johnson
Clockwise from top left, Reps. Abigail D. Spanberger (D-Va.), Cindy Axne (D-Iowa), David McKinley (R-W.Va.), Doris Matsui (D-Calif.), John Katko (R-N.Y.), and Dusty Johnson (R-S.D.) are urging fellow House members to sign a letter urging HHS to begin 340B enforcement actions against drug companies.

Six U.S. House members—three Democrats and three Republicans—are urging fellow representatives to sign a letter asking U.S. Health and Human Services (HHS) Department leaders “to begin enforcement actions against pharmaceutical companies that refuse to honor 340B discounts on prescription drugs.”

Read More »

NACHC Tells Merck its 340B Contract Pharmacy Policy for Health Centers Can Be Explained by “Only Greed”

Merck corporate campus outdoor sign and building
NACHC's president and CEO told her counterpart at Merck the company's decision to impose conditions on 340B on health centers, but not on other grantee covered entities, "cannot be explained by logic, only greed.”

The National Association of Community Health Centers this week strongly urged drug manufacturer Merck to eliminate “all conditions imposed on health centers to receive 340B price drugs at contract pharmacies.”

Merck’s April 28 decision to extend its restrictions on 340B pricing

Read More »

Breaking News

U.S. Supreme Court Strikes Down Medicare Part B Drug Payment Cuts for 340B Hospitals in 2018 and 2019

Statue and Corinthian capitals at the entrance to the Supreme Court building
The U.S. Supreme Court today struck down deep Medicare Part B drug reimbursement cuts for many 340B hospitals during 2018 and 2019. The decision does not affect continuation of the cuts in 2020 through this year, however.

UPDATE, June 15, 2022, 12:45 p.m. EDT—The U.S. Centers for Medicare & Medicaid Services said, “We are aware and reviewing the decision.”


The U.S. Supreme Court ruled unanimously this morning that the federal government unlawfully slashed Medicare Part

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live